Navigation Links
Drug Found Ineffective Against Lung Disease
Date:6/30/2009

People with idiopathic pulmonary fibrosis gain no survival benefit, research finds,,

MONDAY, June 29 (HealthDay News) -- Treatment with interferon gamma-1b (Ifn-g1b) does not improve survival in people with a fatal lung disease called idiopathic pulmonary fibrosis, according to a study that was halted early after no benefit to participants was found.

Previous research had suggested that Ifn-g1b might benefit people with idiopathic pulmonary fibrosis, particularly those with mild to moderate disease.

The new study included 826 people, ages 40 to 79, who lived in Europe and North America. They were given injections of either 200 micrograms of Ifn-g1b (551 people) or a placebo (275) three times a week.

After a median of 64 weeks, 15 percent of those in the Ifn-g1b group and 13 percent in the placebo group had died. Symptoms such as flu-like illness, fatigue, fever and chills were more common among those in the Ifn-g1b group than in the placebo group. The two groups had similar rates of serious side effects, the researchers found.

"We cannot recommend treatment with interferon gamma-1b since the drug did not improve survival for patients with idiopathic pulmonary fibrosis, which refutes previous findings from subgroup analyses of survival in studies of patients with mild-to-moderate physiological impairment of pulmonary function," Dr. Talmadge E. King Jr., of the University of California, San Francisco, and colleagues wrote in the study published online and in an upcoming print issue of The Lancet.

The negative findings of this study "should be regarded as definite, [but] they should not discourage patients to participate in one of the several clinical trials currently underway to find effective treatments for this devastating disease," Dr. Demosthenes Bouros, of the Democritus University of Thrace in Greece, wrote in an accompanying editorial.

Bouros added that people deemed suitable "should be enrolled early in the transplantation list, which is today the only mode of treatment that prolongs survival."

More information

The U.S. National Heart, Lung and Blood Institute has more about idiopathic pulmonary fibrosis.



-- Robert Preidt



SOURCE: The Lancet, news release, June 29, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Sudden Cardiac Arrest Foundation Mourns the Loss of Michael Jackson
2. The AGA Foundation awards grant to Dr. Michael Choi to further his research on carcinoid tumors
3. New piece found in colorectal cancer puzzle
4. AUA Foundation announces 2009 Research Scholar Program award winners
5. AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
6. Jennifer Dodson, M.D., named 2009 AUA Foundation/NIDDK/NCI Surgeon-Scientist Award winner
7. The Crohns & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners
8. Elizabeth Edwards to Deliver Keynote Address at Patient Advocate Foundations 10th Annual Patient Congress
9. Virtuosant Technology Offers Virtuosant Foundation Portal™ for Free
10. The United Nations Foundation Joins White House Initiative to Encourage Public Service
11. Children's National Medical Center Honors The Children's Cancer Foundation for Commitment to Area Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Found Ineffective Against Lung Disease
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology: